PARP1 and myeloid sarcoma: Given PARP1 activation in multiple lineage cells of MS patients and EAE animal models including T and B lymphocytes, monocytes, DCs, macrophages, microglia, OLs, astrocytes, and neurons,[13, 14, 15, 16] the biological effect of PARP1 deficiency/inhibition on different types of immune and neural cells cannot be neglected prior to considering PARP1 as a potential therapeutic target for MS or EAE.